Analysis of anti-tumor prescription comments in outpatient department of Hefei Second People's Hospital
Objective To understand the anti-tumor prescriptions in the outpatient department of Hefei Second People's Hospital(hereinafter referred to as"our hospital")and improve the overall level of special comments.Methods The anti-tumor prescriptions and adverse reaction reports issued by the outpatient department of our hospital from January 2020 to December 2021 were screened,the reasons for unreasonable prescriptions were analyzed by Pareto chart,and the evalua-tion was carried out in combination with clinical application management indicators.Results A total of 2 463 anti-tumor prescriptions were included,a total of 294 unreasonable prescriptions were obtained.A total of 1 857 were common and 606 were restricted anti-tumor drug prescriptions,and the consumption amount was 3 452 438.04 yuan and 847 884.90 yuan,respectively.The qualified rate of prescriptions was 88.06%,and the success rate of prescription intervention was 90.14%.The total number of adverse reaction reports in outpatient department was 2 296,among which the total number of adverse reaction reports of anti-tumor drugs was 285,and the number of serious and new adverse reaction reports of anti-tumor drugs was eight and seven,respectively.The main groups of irrational prescriptions were people over 60 years old.Urology,hemato-oncology,respiratory medicine,and neurology were the main departments involved in unreason-able prescription.Tumor,hypertension,diabetes,and cerebral infarction were the main diagnoses of irrational prescription.Over-prescribing and inappropriate indications were the main and secondary types of irrational prescribing.Conclu-sion The qualified rate of antitumor prescriptions and the success rate of intervention in the outpatient department of our hospital are low,and there are many unreasonable reasons.Clinical pharmacists should regularly make special comments and take measures based on clinical application management indicators and Pareto chart to ensure the drug safety of tumor patients.